drugset
drugset / Trial / NCT04584307

Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant

NCT04584307 ↗

Phase 2 Withdrawn Natalie Callendar Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this clinical trial is to examine the role of an immune modulatory drug (IMID) in combination with elotuzumab, in a lenalidomide-free approach to maintenance therapy following second unplanned autologous peripheral blood stem cell transplant (PBSCT) for relapsed multiple myeloma.

Timeline

Start
2021-04
Primary completion
2023-12
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Elotuzumab Monoclonal antibody 10 mg/kg Intravenous
Subject Elotuzumab Monoclonal antibody 20 mg/kg Intravenous
Subject Pomalidomide Other / unclassified 2 mg Oral

Indications

plasma cell myeloma